Sobi to present new data across its immunology portfolio at the ACR Convergence 2024 WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of four abstracts that...

Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting Sobi will present three abstracts that highlights data from its myelofibrosis treatment option at ASCO.

Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome FDA has granted Fast Track designation to emapalumab-lzsg for the potential first therapeutic option in patients with MAS

Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia

Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome WALTHAM, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), today announced that the Annals of Rheumatic...